CJC-1295 references: every source behind the published record

How to read the references on this site

These CJC-1295 references represent the published research record for the compound. The literature is specific. It's quite narrow. Human data rest on two clinical trials from 2006 that tested hormone changes in healthy adult volunteers ^{[1] [3]}. Foundational animal studies from 2005 and 2006 confirmed how the chemical binds to blood albumin ^[2]. A follow-up mouse study from 2006 verified growth restoration in rodents ^[4].

When reading studies about CJC-1295, you need to check which form was administered. Research on CJC-1295 with DAC describes multi-day hormone elevation. Studies on Modified GRF describe pulses lasting thirty minutes. Laboratory papers investigating two separate biological routes show how growth messengers act alongside ipamorelin in animal cells ^{[7] [8] [9]}. Regulatory reviews from 2024 document safety evaluations and restrictions on custom mixing in compounding pharmacies. Every factual claim on this site points to one of these numbered papers for your inspection. That's how you check the evidence.

How studies are grouped between human trials and animal tests

The references fall into three distinct groups. You can weigh them separately. The first group contains early human clinical studies from 2006 that measured growth hormone in healthy volunteers ^{[1] [3]}. A related trial from 2009 tracked rises in blood carrier proteins ^[5]. Those proteins travel alongside liver-produced IGF-1. These papers show what a single injection does. They document short-term blood changes in healthy people.

The second group includes foundational animal experiments from 2005 and 2006 in rats and mice ^{[2] [4]}. These laboratory animal papers tested the compound in rodents. Tests began before human trials started. A related 2006 study verified normal daily growth in mice that lacked their own growth gene. Additional laboratory studies describe how growth messengers interact with ipamorelin in animal cells ^{[7] [8] [9]}. Animal tests provide clues. They track how fast rodent blood clears ipamorelin ^{[10] [11]}.

The third group compares CJC-1295 with similar growth drugs and explains forensic testing methods. Forensic chemical testing confirmed CJC-1295 inside unlicensed vials sold on the black market ^[6]. Anti-doping papers describe detection methods used in competitive sports ^{[12] [13]}. Overviews from 2025 and 2026 evaluate the medical research on growth peptides ^{[14] [15]}. They give a broad summary. They confirm that daily fitness benefits and long-term safety for this compound remain unproved in humans. That is the current scientific consensus.